Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 4/20 | 0.65 |
| ▸ | CDK2 | P24941 | 3/20 | 0.65 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.65 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.65 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.64 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.59 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.59 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 0.59 |
| ▸ | GSK3B | P49841 | 4/20 | 0.59 |
| ▸ | CSNK1G2 | P78368 | 4/20 | 0.59 |
| ▸ | PRKD2 | Q9BZL6 | 4/20 | 0.59 |
| ▸ | CSNK1G1 | Q9HCP0 | 4/20 | 0.59 |
| ▸ | CSNK1G3 | Q9Y6M4 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.59 |
| ▸ | GSK3A | P49840 | 3/20 | 0.59 |
| ▸ | TAOK1 | Q7L7X3 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368356 | 0.88 | MAPK14 (0.62) | CSNK1ECDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL20969793 | 0.88 | MAPK14 (0.62) | CSNK1ECDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL4300868 | 0.85 | MAP4K4 (0.55) | CSNK1ECDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL12023544 | 0.82 | CSNK1E (0.64) | CSNK1ECDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL12154383 | 0.82 | MAPK9 (0.70) | CDK2MAPK14CSNK1DPRKD3MAP4K4 | |
| SCHEMBL1730877 | 0.81 | PRKD3 (0.58) | CSNK1ECDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL12023375 | 0.80 | PRKD3 (0.60) | CSNK1ECDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL12154474 | 0.80 | PRKD3 (0.67) | CSNK1ECDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL12023423 | 0.79 | PRKD3 (0.82) | CDK2MAPK14CSNK1DPRKD3MAP4K4 | |
| SCHEMBL12023411 | 0.79 | MAPK9 (0.72) | CDK2MAPK14CSNK1DPRKD3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| EP-1633758-B1 | IMIDAZOTHIAZOLES AND IMIDAZOXAZOLE DERIVATIVES AS INHIBITORS OF P38 | ARQULE INC (US) | 2011-11-23 | — | — | EP | disclosed |
| EP-1633758-B1 | IMIDAZOTHIAZOLES AND IMIDAZOXAZOLE DERIVATIVES AS INHIBITORS OF P38 | ARQULE INC (US) | 2011-11-23 | — | — | EP | disclosed |
| US-7902192-B2 | Inhibitors of P38 and methods of using the same | ARQULE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902192-B2 | Inhibitors of P38 and methods of using the same | ARQULE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902192-B2 | Inhibitors of P38 and methods of using the same | ARQULE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2251343-A1 | IMIDAZOTHIAZOLES AS P38-KINASE-INHIBITORS | ARQULE, INC. (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-2251343-A1 | IMIDAZOTHIAZOLES AS P38-KINASE-INHIBITORS | ARQULE, INC. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | MAPK1, MAPK8, MAPK7 | CSNK1E 730/4885CDK2 393/4885CCNA2 2545/4885 |
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | MAPK1, MAPK7, MAPK8 | CSNK1E 677/4885CDK2 367/4885CCNA2 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.